Form 4: Perceptive Advisors and Affiliates Report Acquisition of Solid Biosciences Stock Options

Perceptive Advisors LLC, a 10% owner and director of Solid Biosciences Inc., reported the acquisition of 77,500 director stock options with an exercise price of $4.58, granted to Adam Stone for his board service.

Summary

• Perceptive Advisors LLC, Perceptive Life Sciences Master Fund Ltd., and Joseph Edelman, all identified as 10% owners and directors of Solid Biosciences Inc. (SLDB), filed a Form 4.
• The filing reports the acquisition of 77,500 director stock options on June 12, 2025.
• These options have an exercise price of $4.58 per share and are set to expire on June 12, 2035.
• The options were granted to Adam Stone, Chief Investment Officer of Perceptive Advisors, LLC, in connection with his role as a member of Solid Biosciences' Board of Directors.
• The options vest fully on the earlier of the one-year anniversary of the grant date (June 12, 2026) or immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date.
• Full vesting also occurs automatically as to 100% of the unvested portion upon specified change in control events.
• Perceptive Advisors, LLC may have an indirect pecuniary interest in these options due to a partial management fee offset.
• Joseph Edelman, Perceptive Advisors, LLC, and Perceptive Life Sciences Master Fund Ltd. disclaim beneficial ownership for Section 16 purposes, except to the extent of their indirect pecuniary interest.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. It's a routine compensation event, but the grant to a representative of a major investor can be seen as a positive alignment of interests.

Positives

• The grant of stock options to a director, particularly one representing a significant institutional investor like Perceptive Advisors, aligns his interests with long-term shareholder value creation.
• The vesting schedule, including accelerated vesting upon a change of control, provides incentives for strategic transactions that could benefit shareholders.

Future Outlook

The vesting schedule for the granted options indicates a forward-looking incentive structure, aligning the director's interests with the company's performance over the next year or until the next annual meeting, with accelerated vesting upon a change of control event.

Management Comments

• "This option was granted on June 12, 2025 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."
• "Mr. Stone is the Chief Investment Officer of Perceptive Advisors, LLC (the 'Advisor'). The Advisor may be deemed to have an indirect pecuniary interest in the options to purchase common stock of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Stone's board service through a partial management fee offset."
• "Joseph Edelman is the managing member of the Advisor. The Advisor serves as the investment manager to Perceptive Life Sciences Master Fund Ltd. (the 'Master Fund'). Each of Mr. Edelman, the Advisor and the Master Fund disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, the Advisor or the Master Fund is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."

Industry Context

This filing represents a standard practice of compensating board members with equity, particularly common in the biotechnology and life sciences sectors where long-term value creation is paramount. The grant to a representative of a significant institutional investor like Perceptive Advisors reinforces alignment between major shareholders and company leadership.

Comparison to Industry Standards

• The grant of 77,500 stock options to a director, with an exercise price of $4.58, is a common form of equity compensation for board members in the biotech industry.
• While specific comparable companies or projects are not detailed in this filing, such grants are typically benchmarked against peer group compensation practices to ensure competitive and motivating incentives for directors, especially those representing significant investors like Perceptive Advisors.

Corporate Governance

Related Party Transactions

• The options were granted to Adam Stone, who is the Chief Investment Officer of Perceptive Advisors, LLC, a 10% owner and director of Solid Biosciences Inc. Perceptive Advisors, LLC may have an indirect pecuniary interest in these options through a partial management fee offset.

Stakeholder Impact

• Shareholders: The grant of options to a director, especially one representing a significant investor, aligns management incentives with shareholder interests, potentially leading to better long-term value creation.
• Management/Directors: Adam Stone receives equity compensation, incentivizing his performance and commitment to the company.

Next Steps

• The options will vest based on the specified schedule (one-year anniversary of grant or next annual meeting, or change of control).
• The options can be exercised by the holder at the exercise price of $4.58 per share until the expiration date of June 12, 2035.

Key Dates

Recommendation

Keywords

Solid Biosciences Inc., SLDB, SEC Form 4, Beneficial Ownership, Stock Options, Director Compensation, Perceptive Advisors LLC, Adam Stone, Joseph Edelman, Insider Transaction, Equity Grant